ReviR Therapeutics Raises $30 Million Series A Financing to Advance its Proprietary Oral Genetic Medicines for Multiple CNS Disorders
Summary
The financing was led by Lapam Capital with strong support from existing investors CDH Investments, 5Y Capital, and Yael Capital, as well as new participants XtalPi and the Charcot-Marie Tooth Research Foundation (CMTRF).These funds will be used to further augment ReviRs AI-driven drug discovery VoyageR platform, which will be leveraged to advance proprietary chemical matter for novel and undruggable targets and to support clinical development of treatments for Huntingtons disease (HD), Charcot-Marie-Tooth disease (CMT), amyotrophic lateral sclerosis (ALS), and other neurological disorders.Since its founding in 2021, ReviR Therapeutics has assembled an expert global drug discovery team and built a robust customized AI platform. ReviRs platform strategy focuses on developing non-invasive, orally administered genetic therapies that use small molecules to regulate RNA splicing and influence protein expression. Our collective expertise is aimed at propelling these innovations into clinical research, tapping into the vast and underexplored potential of RNA targets, and delivering effective novel therapeutic options to patients worldwide. The Company combines quantum physics, AI, cloud computing, and large-scale robotics to provide R&D solutions and services for biomedicine, chemical, renewable energy and advanced materials industries globally.CMT Research Foundation (CMTRF) is a patient-led, non-profit focused on delivering treatments and cures for CMT. Founded by two patients who are driven to expedite drug delivery to people who live with CMT, the 501(c)(3) federal tax-exempt organization is supported by personal and corporate financial gifts.